Drugs that contain Dexmedetomidine Hydrochloride

1. Drug name - DEXMEDETOMIDINE HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649296 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container Apr, 2036

(13 years from now)

US9717796 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container Apr, 2036

(13 years from now)

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - PRECEDEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US10016396 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8338470 HOSPIRA Dexmedetomidine premix formulation Jan, 2032

(9 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation Jul, 2032

(9 years from now)

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) INJECTABLE;INJECTION Prescription

availability in other generic markets.

Click on the highlighted region to filter.